Moderna (MRNA) Revenue — Quarter Ended Dec 31, 2024
Revenue declined sharply in the current quarter compared to both the prior quarter and the same quarter a year ago. The decrease reflects a continuation of the downward trend seen in the trailing twelve months.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 Q4
Revenue declined sharply in the current quarter compared to both the prior quarter and the same quarter a year ago. The decrease reflects a continuation of the downward trend seen in the trailing twelve months.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$966M
Revenue reported for this quarter.
Quarter-over-quarter
-48.1%
Change from the immediately preceding quarter.
Year-over-year
-65.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$3.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $167M | -91.0% |
| Jun 30, 2024 | $241M | -29.9% |
| Sep 30, 2024 | $1.9B | +1.7% |
| Dec 31, 2024 | $966M | -65.6% |
Revenue performance
Reported revenue for the quarter was lower than the immediately preceding quarter, marking a significant sequential drop. The year-over-year comparison also showed a substantial decline.
Quarterly comparison
Compared to the prior quarter, revenue decreased notably, and relative to the same quarter one year earlier, the decline was even more pronounced. The trailing twelve-month revenue figure was substantially higher than the current quarter's result.
What to watch
The company's cash and investments decreased year over year, primarily due to operating cash outflows and capital expenditures.